Mankind Pharma has announced a strategic partnership with Denovo Sciences to enhance its drug discovery efforts through artificial intelligence.
This collaboration aims to leverage Mankind Pharma’s research and clinical development strengths alongside Denovo Sciences’ advanced AI platform for molecular generation and prioritization. The approach integrates a human-in-the-loop model, where AI assists in generating and assessing molecular candidates, while scientists provide validation and refinement throughout the discovery process.
The partnership is designed to accelerate early drug discovery timelines, enhance the quality of lead candidates, and improve the chances of success in clinical trials by facilitating more informed decision-making from the outset of research. Mankind Pharma's COO, Arjun Juneja, emphasized that this initiative will not only expedite the drug discovery process but also maintain a strong focus on scientific rigor. Dr. Anil Koul, the Group Chief Scientific Officer, noted that innovative AI technologies are reshaping pharmaceutical R&D and will bolster Mankind’s commitment to being an innovation-driven company.
Denovo Sciences’ CEO, Hovakim Zakaryan, highlighted that the synergy between their AI platform and Mankind Pharma’s scientific expertise is crucial for identifying promising drug candidates more efficiently. This partnership signifies a pivotal advancement in Mankind Pharma’s journey towards AI-enhanced drug development and aligns with Denovo Sciences’ goal of utilizing AI to improve patient outcomes.